Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Bio-Rad launches RNA library prep kit

September 2022—Bio-Rad Laboratories has launched its SEQuoia Express Stranded RNA Library Prep Kit. The three-tube kit uses a novel reverse transcriptase with ligation-free adapter addition chemistry to yield a reproducible, quantitative RNA sequencing library in three hours. The kit enables users to construct robust libraries that capture mRNA and long noncoding RNA (>200 bp) transcripts for differential gene expression analysis and novel transcript discovery.

Roche COVID-19 test detects, differentiates BA.2.75

September 2022—Roche and its subsidiary TIB Molbiol have developed a COVID-19 test that detects and differentiates the BA.2.75 subvariant. The VirSNiP SARS-CoV-2 Spike 147E 152R test, for research use only, targets two of the known unique mutations, K147E and W152R, in BA.2.75, which allows clear differentiation against other notable subvariants. The test is for use on the Lightcycler and Cobas z480 instruments and is available worldwide.

Thermo Fisher launches HIV-1 genotyping kit

September 2022—Thermo Fisher Scientific launched its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus to identify genetic variants that resist common antiretroviral therapeutics.

Bio-Rad launches two negative run controls

August 2022—Bio-Rad Laboratories launched two new Exact Diagnostics products. The Exact Diagnostics Synthetic Negative Run Control is screened negative for nine targets, Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, enterovirus coxsackievirus A9, HSV-1 and HSV-2, and varicella zoster virus. The Exact Diagnostics HAI Negative Run Control is screened negative for Clostridium difficile, methicillin-resistant Staphylococcus aureus, and methicillin-susceptible Staphylococcus aureus.

Thermo Scientific, Inpeco to develop LC-MS/MS, TLA connectivity

August 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco S.A. FlexLab total laboratory automation system.

CorePath, Cizzle Biotech to develop early-stage lung cancer test

August 2022—CorePath Laboratories announced a partnership with U.K.-based diagnostics developer Cizzle Biotech to develop and offer a proprietary early-stage lung cancer test throughout the United States. Cizzle Biotech’s proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, Cizzle Biotech says, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

MARKETPLACE

TRENDING